dotMD.com
Find a Doctor
✓ Translated by DotMD AI Clinical Council Source: Amyotrophic lateral sclerosis & frontotemporal degeneration • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40503807 ↗

Phase III Randomized Trial: Hospitalizations as an outcome measure in COURAGE-ALS

Original Paper Title: “Hospitalizations as an outcome measure in COURAGE-ALS”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Conclusion : While most hospitalizations in COURAGE-ALS were HR-ALS, HU-ALS and HI-ALS also occurred. When using hospitalization as an endpoint in an ALS clinical trial, recording its relationship to ALS provides additional details to characterize disease burden and clinical meaningfulness of the endpoint.
  • Study Design & Sample: Phase III Randomized Trial published in Amyotrophic lateral sclerosis & frontotemporal degeneration (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Amyotrophic lateral sclerosis & frontotemporal degeneration (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Objective : To describe the development of a methodology to characterize hospitalizations and their relationship to amyotrophic lateral sclerosis (ALS) and provide results using this process in a phase 3 trial of reldesemtiv in ALS. Key clinical takeaway: Conclusion : While most hospitalizations in COURAGE-ALS were HR-ALS, HU-ALS and HI-ALS also occurred. When using hospitalization as an endpoint in an ALS clinical trial, recording its relationship to ALS provides additional details to characterize disease...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Amyotrophic lateral sclerosis & frontotemporal degeneration, 2025-11-15; Phase III Randomized Trial; Rigor 88/100): Conclusion : While most hospitalizations in COURAGE-ALS were HR-ALS, HU-ALS and HI-ALS also occurred. When using hospitalization as an endpoint in an ALS clinical trial, recording its relationship to ALS provides additional details to characterize disease burden and clinical meaningfulness of the endpoint.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: crest-pro-health-cetylpyridinium-chloride → Rx: health-smart-vaporizing-chest-rub-menthol-and-camphor-and-eucalyptus-oil → Condition: blushing → Condition: arteriovenous-shunt →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40503807: Phase III Randomized Trial: Hospitalizations as an outcome measure in COURAGE-ALS

3 of 3 Free Questions Remaining